Clinical Trial Update: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 2/Phase 3 study evaluating atezolizumab and/or bevacizumab with or without standard chemotherapy for second-line tr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cutaneous Squamous Cell Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Hypopharyngeal Cancer
• Laryngeal Cancer
• Nasopharyngeal Cancer
• Oral Cavity Cancer
• Oropharyngeal Cancer
• Sinonasal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING